Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

Summary

Background: Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cyclophosphamide (CYC). But CYC can damage a woman s ovaries; it may cause infertility. A drug called GnRHa is sometimes given to protect the ovaries during CYC therapy. But no one really knows how effective GnRHa treatment is. This natural history survey will compare women who received GnRHa during CYC therapy with those who did not. Objective: To find out whether GnRHa can help protect women s ovaries during CYC.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Systemic Lupus Erythematosus (Sle)
• Primary Ovarian Insufficiency (Poi)

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

18 to 120 years

Sex

Female

Healthy volunteers

Not accepted

Sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Last updated on ClinicalTrials.gov

September 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites